Combo Cancer Drugs Outperform Chemo Alone in Key Breast Cancer Subgroups
Recent research presented at the European Society for Medical Oncology (ESMO) meeting shows that antibody-drug conjugates (ADCs) significantly improve outcomes for certain breast cancer patients when used alongside chemotherapy. For patients with aggressive triple-negative breast cancer who cannot get immunotherapy, Trodelvy extended median progression-free survival to 9.7 months, compared to 6.9 months with standard chemo….
